Physician

Hematology

Dr. Paul Y. Holoye is an expert in the field of Hematology. He graduated from Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai is ranked 20/62 in Research/PrimaryCare. He has 1 awards "Super Doctor". Paul Y. Holoye, MD is also a published MD. He has 62 paper published. The most recent paper is: Neurocardiogenic syncope and Prinzmetal's angina associated with bronchogenic carcinoma. Paul Holoye accepts all Medicare patients.

Publications

---

• Spontaneous pneumocephalus associated with recurrent colorectal carcinoma.
• Neurocardiogenic syncope and Prinzmetal's angina associated with bronchogenic carcinoma.
• Phase II clinical trial of didemnin B in previously treated small cell lung Cancer.
• Prophylaxis of ifosfamide toxicity with Oral acetylcysteine.
• Adenocarcinoma of prostate presenting as Brain metastasis.
• The influence of myelosuppression on the response to chemotherapy in Small cell bronchogenic carcinoma.
• Spinal cord metastasis in small cell carcinoma of the Lung.
• Changes in the relative risk and sites of central nervous system metastasis with effective combined chemotherapy and radiation therapy for Small cell carcinoma of the ...
• Use and safety of high-dose ifosfamide.
• Integration of chemotherapy and radiation therapy for small cell carcinoma of the Lung.
• The role of consolidation irradiation in combined modality therapy of small cell carcinoma of the Lung.
• The role of thoracic and cranial irradiation for small cell carcinoma of the Lung.
• Local control of intrathoracic disease with chemotherapy and role of prophylactic cranial irradiation in small-cell carcinoma of the Lung.
• The prognostic significance of histologic subtyping in small cell carcinoma of the Lung.
• What is the lowest effective biologic dose for prophylactic cranial irradiation?
• Phase II study of spirogermanium in advanced (extensive) non-small cell lung Cancer.
• I.v. melphalan in carcinoma of the Lung: effect of cyclophosphamide priming on hematopoietic toxicity.
• Priming: theory or fact?
• "Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial".
• Multiagent chemotherapy, prophylactic neuraxis irradiation, and consolidative irradiation for small cell carcinoma of the Lung.
• Relationship between myelosuppression and chemotherapeutic response in Small cell bronchogenic carcinoma.
• Combined methotrexate and high-dose vincristine chemotherapy with radiation therapy for Small cell bronchogenic carcinoma.
• Phase II study of tiazofurin (NSC 286193) in the treatment of advanced Small cell bronchogenic carcinoma.
• Phase II pilot study with cisplatin, etoposide, and continuous-infusion 5-fluorouracil in metastatic non-small cell lung Cancer.
• Phase II study of idarubicin in extensive-disease non-small-cell lung Cancer.
• Primary chemotherapy of brain metastasis in small-cell lung Cancer.
• Phase II study of 5,6-dihydro-5-azacytidine in extensive, untreated non-small cell lung Cancer.
• A randomized study of adjuvant chemotherapy for Cancer of the upper aerodigestive tract.
• Randomized study of adjuvant chemotherapy for head and neck Cancer.
• The role of adjuvant surgery in the combined modality therapy of Small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission.
• Intrapleural etoposide for Malignant effusion.
• Ifosfamide with mesna uroprotection in the management of lung Cancer.
• Adjuvant surgery in the multimodality treatment of small-cell lung Cancer.
• Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell Lung carcinoma.
• Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-Small cell bronchogenic carcinoma.
• Phase I/II clinical trial of didemnin B in non-small-cell lung Cancer: neuromuscular toxicity is dose-limiting.
• Resectability of small-cell lung cancer following inDuction chemotherapy in patients with limited disease (stage II-IIIb).
• Phase II trial of trimetrexate for unresectable or metastatic non-Small cell bronchogenic carcinoma.
• Paraneoplastic Cushing's Syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer.
• Pulmonary toxicity in long-term administration of BCNU.
• Combination vincristine (NSC-67574) and hydroxyurea (NSC-32065) for metastatic renal carcinoma.
• Lactic acidosis and death owing to Cancer.
• A clinical evaluation of the triple-isotope double-antibody radioimmunoassay for carcinoembryonic antigen.
• Endocrine studies in Testicular tumor patients with and without gynecomastia: a report of 45 cases.
• Management of Small-cell bronchogenic carcinoma.
• Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
• Chemoimmunotherapy of Small cell bronchogenic carcinoma.
• Combination chemotherapy and radiation therapy for Small cell carcinoma.
• Cyclophosphamide, vincristine and sequential split-course radiotherapy in the treatment of small cell lung Cancer.
• Combination chemotherapy of head and neck Cancer.
• The pharmacokinetics of bleomycin in man.
• Bleomycin hypersensitivity pneumonitis.
• Clinical pharmacology of bleomycin following intraVenous infusion as determined by radioimmunoassay.
• Combination chemotherapy in germinal cell tumors.
• Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronc...
• Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy.
• Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III Testicular neoplasia.
• Bleomycin combination chemotherapy in the management of Testicular neoplasia.
• Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma.
• Combination chemotherapy with bleomycin (NSC-125066), vincristine (NSC-67574), and methotrexate (NSC-740) plus split-course radiotherapy in the treatment of non-oat-ce...
• Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.

Schools

---

• Universite Libre De Bruxelles Faculte De Medecine

• Washington Hospital Center

• Bronx Va Hospital

• Mt Sinai Hospital

• MD Anderson Tumor Institute

Procedures Preformed

---

• Biopsy
• Chemotherapy for Treatment of Gynecologic Cancer

Conditions Treated

---

• Antiphospholipid Syndrome (APS)
• Bile Duct Cancer
• Brain Cancer
• Deep Vein Thrombosis (DVT)
• View All

Doctors Specialties

---

• Adult Hematology
• Internal Medicine
• Medical Oncology
• Hematology

Accepted Insurances

---

Awards

---

• Super Doctor

Education

---

• University of Texas MD Anderson Cancer Center
• Icahn School of Medicine at Mount Sinai
• Georgetown University Hospital - Washington Hospital Center

Hospital

---

• Park Plaza Hospital
• Memorial Hermann Memorial City Medical Center
• St. Joseph Medical Center
• Baylor St. Luke's Medical Center

Drug Facts

---

NPI NUMBER		1497716401
NPPES Provider LastName		HOLOYE
NPPES Provider FirstName		PAUL
NPPES Provider ZIPCode		770303304
NPPES Provider State		TX
Specialty Description		Medical Oncology
Total Claim Count		442.0
Distinct Opioid Count		2.0
Opioid Claim Count		39.0
Percent Opioid Claims		8.82

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1497716401
Last Name Of The Provider	HOLOYE
First Name Of The Provider	PAUL
View All

Similar Doctors

---

	Dr. Edward H. Mazique, MD This Doctor is OpenDoctor Recommended.
	Dr. Quan H. Le, MD This Doctor is OpenDoctor Recommended.
	Dr. Niraj N. Mehta, MD This Doctor is OpenDoctor Recommended.
	Dr. Bhavesh Bhatt, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard C. Lock, MD This Doctor is OpenDoctor Recommended.
	Dr. Nicolas A. Villa, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas M. Mendler, MD This Doctor is OpenDoctor Recommended.
	Dr. Douglas Magee, MD
	Dr. Megan D. McCain, MD
	Dr. Zeev Estrov, MD This Doctor is OpenDoctor Recommended.
	Dr. David B. Sanford, MD This Doctor is OpenDoctor Recommended.
	Dr. Luhua M. Wang, MD This Doctor is OpenDoctor Recommended.
	Dr. Cristhiam M. Rojas, MD This Doctor is OpenDoctor Recommended.
	Dr. Krishna K. Pachipala, MD This Doctor is OpenDoctor Recommended.
	Dr. Monisha Singh, MD This Doctor is OpenDoctor Recommended.
	Dr. Tejash R. Patel, MD This Doctor is OpenDoctor Recommended.
	Dr. Maria A. Rodriguez, MD This Doctor is OpenDoctor Recommended.
	Dr. Ethan A. Natelson, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Susan M. Escudier, MD This Doctor is OpenDoctor Recommended.
	Dr. Sumit K. Subudhi, MD This Doctor is OpenDoctor Recommended.
	Dr. David L. Ramirez, MD
	Dr. Thomas P. Haynie III, MD This Doctor is OpenDoctor Recommended.
	Dr. Padmanee Sharma, MD This Doctor is OpenDoctor Recommended.
	Dr. Sao Jiralerspong, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel E. Epner II, MD This Doctor is OpenDoctor Recommended.
	Dr. Anthony P. Conley, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles Lu, MD This Doctor is OpenDoctor Recommended.
	Dr. Sindhu Nair, MD This Doctor is OpenDoctor Recommended.
	Dr. Luis E. Fayad, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael A. Davies, MD This Doctor is OpenDoctor Recommended.
	Dr. Karin Hahn, MD This Doctor is OpenDoctor Recommended.
	Dr. Yuval Raizen, MD This Doctor is OpenDoctor Recommended.
	Dr. Annie R. Su, MD This Doctor is OpenDoctor Recommended.
	Dr. Julio A. Peguero, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog